Perimeter Medical Imaging AI (PINK) AI Stock Analysis

• Market Cap: C$26.74M
• Dividend Yield: N/A
• Average Volume (3M): 57.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: 219.12%
• EPS Growth: -15.92%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): -0.06
• Shares Outstanding: 113,771,920
• 10 Day Avg. Volume: 71,336
• 30 Day Avg. Volume: 57,607
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$3.00
• Price Target Upside: 1150.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Perimeter Medical Imaging AI's overall score is driven by financial performance challenges, including profitability and cash flow issues. While the earnings call showed positive revenue growth and operational improvements, the stock's valuation and technical indicators suggest caution. The company's ability to address cash flow and profitability will be crucial for future performance.

Perimeter Medical Imaging AI Business Overview & Revenue Model

Company Description

Perimeter Medical Imaging AI, Inc., a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The company offers an optical coherence tomography (OCT) imaging system provides clinicians with cross-sectional of tissues down to 2 mm dept. This OCT imaging system consists of S-series OCT, B-series OCT, and OCT imaging console. It also offers ImgAssist, an artificial intelligence technology that enhances the efficiency of image review and be an additional powerful tool when combined with Perimeter OCT to aid physicians with real-time margin visualization and assessment to improve surgical outcomes for patients and reducing the likelihood of needing additional surgeries. In addition, the company offers proprietary image library and consumable specimen containers to hospitals and cancer surgery centers. Perimeter Medical Imaging AI, Inc. was founded in 2013 and is headquartered in Toronto, Canada.

How the Company Makes Money

Perimeter Medical Imaging AI generates revenue primarily through the sale and distribution of its proprietary imaging systems to hospitals and surgical centers. The company's revenue model includes direct sales of its devices, as well as recurring revenue from service and maintenance contracts, and potentially from software licenses for its AI-driven platform. Key revenue streams also include partnerships with healthcare institutions and collaborations with research organizations that leverage its technology for clinical studies and advancements in surgical oncology. Additionally, strategic alliances and collaborations with other medical technology firms can contribute to its earnings by expanding the reach and application of its imaging solutions.

Perimeter Medical Imaging AI Financial Statement Overview

Summary

Perimeter Medical Imaging AI exhibits strong revenue growth but continues to face significant profitability challenges with a high net loss and negative cash flow. The balance sheet shows low leverage, which is good for stability, but declining equity and assets are concerns. Overall, the company is in a growth phase but needs to improve operational efficiencies to achieve sustainable financial health.

Income Statement

Perimeter Medical Imaging AI has shown significant revenue growth with a TTM revenue of $1,298,133 compared to $846,194 in the previous year. However, the company continues to operate at a net loss, with a TTM net income of -$15,589,354, indicating ongoing challenges in achieving profitability. The gross profit margin is healthy at 60.6%, but the net profit margin remains negative due to high operating expenses.

Balance Sheet

The company's balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.02, indicating low leverage. However, stockholders' equity has decreased over the past year, and the equity ratio stands at 75.9%. The reduction in total assets and equity might pose potential risks if the trend continues without a corresponding increase in profitability.

Cash Flow

Cash flow analysis shows challenges with a negative free cash flow of -$17,114,155 for TTM, indicating cash burn issues. The operating cash flow to net income ratio is slightly negative, which suggests difficulties in converting operational activities into cash. Despite negative cash flows, the company has managed to secure financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.56M	846.19K	403.53K	132.77K	11.34K	0.00
Gross Profit	968.18K	535.11K	206.42K	100.63K	5.04K	-47.57K
EBITDA	-15.46M	-12.64M	-17.92M	-11.72M	-15.95M	-6.11M
Net Income	-16.29M	-13.39M	-18.94M	-3.59M	-16.76M	-8.00M
Balance Sheet
Total Assets	6.92M	14.33M	27.09M	34.60M	9.98M	13.16M
Cash, Cash Equivalents and Short-Term Investments	1.37M	6.18M	18.43M	28.44M	5.14M	11.70M
Total Debt	117.05K	137.48K	192.89K	325.68K	441.17K	400.81K
Total Liabilities	2.41M	3.87M	7.10M	8.49M	2.56M	2.40M
Stockholders Equity	4.51M	10.45M	15.06M	26.11M	7.42M	10.76M
Cash Flow
Free Cash Flow	-15.78M	-16.90M	-15.17M	-13.86M	-16.03M	-8.26M
Operating Cash Flow	-13.86M	-14.72M	-14.70M	-11.87M	-13.91M	-8.26M
Investing Cash Flow	-1.80M	-1.90M	206.01K	-1.75M	-1.45M	7.24M
Financing Cash Flow	10.44M	8.58M	234.47K	40.28M	10.06M	9.84M

Perimeter Medical Imaging AI Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Neutral. The current price of 0.24 is above the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.25, and below the 200-day MA of 0.40, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.16 is Neutral, neither overbought nor oversold. The STOCH value of 83.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:PINK.

Perimeter Medical Imaging AI Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	66 Neutral	C$155.53M	―	-9.96%	―	-0.70%	-102.48%
ASG	60 Neutral	C$20.29M	―	-26.27%	―	17.61%	-19.19%
PRN	54 Neutral	C$181.22M	―	-106.37%	―	64.42%	-21.09%
Sector *	51 Neutral	$7.92B	-0.43	-41.69%	2.21%	22.29%	-1.85%
TLT	45 Neutral	C$48.84M	―	-291.69%	―	16.00%	9.79%
VPT	44 Neutral	C$17.61M	―	207.08%	―	88.47%	11.88%
PINK	43 Neutral	C$26.74M	―	-233.44%	―	219.12%	-15.92%

Perimeter Medical Imaging AI Corporate Events

Perimeter Medical Imaging AI Raises $5.35 Million in Prospectus Offering

Perimeter Medical Imaging AI, Inc. has successfully closed the final tranche of its prospectus offering, raising a total of approximately $5.35 million. The funds will be used to advance the commercialization of their technology, establish clinical evidence, and continue product development, which could strengthen their market position and benefit stakeholders by enhancing their innovative imaging solutions for cancer surgery.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Medical City Dallas Adopts Perimeter’s Advanced Imaging Technology

Medical City Dallas Hospital has adopted Perimeter Medical Imaging AI’s S-Series OCT technology for high-resolution tissue visualization during surgeries. This adoption follows the hospital’s participation in a pivotal trial of Perimeter’s B-Series device, which integrates AI and is under FDA evaluation for breast-conserving surgeries. The S-Series OCT, cleared by the FDA in 2021, offers cellular-level imaging, making it ideal for surgical margin visualization. This deployment marks a significant step in Perimeter’s nationwide technology rollout, potentially enhancing surgical outcomes and positioning the company as a leader in advanced medical imaging solutions.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI to Present Business Update at Investor Forum

Perimeter Medical Imaging AI announced that its CEO, Adrian Mendes, will present an update on the company’s business at the Life Sciences Virtual Investor Forum. This presentation reflects Perimeter’s ongoing efforts to enhance its industry positioning by showcasing its innovative imaging technologies, which aim to address unmet medical needs in cancer surgery.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Launches OCT-Tissue Registry to Enhance Surgical AI Technology

Perimeter Medical Imaging AI has launched the OCT-Tissue Surveillance Registry to collect images and data from surgeries using their imaging technology. This initiative aims to enhance their AI deep-learning model for investigational technology, potentially improving surgical outcomes and reducing the need for second surgeries. The registry will help in developing a sophisticated AI model by gathering diverse data, which could lead to more personalized patient care and better clinical results.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Completes $3.13 Million Prospectus Offering

Perimeter Medical Imaging AI, Inc. has successfully closed its prospectus offering, raising approximately $3.13 million through the issuance of over 10 million units. The proceeds will support the commercialization of its technology, clinical evidence establishment, and product development. This financial move is expected to bolster Perimeter’s market position and operational capabilities, potentially enhancing its impact on the medical imaging industry.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Announces $2.5 Million Public Offering

Perimeter Medical Imaging AI, Inc. has announced the pricing and terms of its public offering of units, aiming to raise at least $2.5 million through the issuance of a minimum of 8,333,334 securities. The proceeds will be used to further commercialize its technology and support product development, with the offering expected to attract U.S. institutional investors and company insiders. The offering is subject to regulatory approvals and is expected to close on or around June 3, 2025, with the potential to raise up to $15 million in total.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Partners with Intermountain Health to Study OCT and AI Benefits

Perimeter Medical Imaging AI has partnered with Intermountain Health to explore the clinical, social, and economic benefits of using its OCT and AI technologies to reduce cancer reoperations. This collaboration will initially involve a study on breast-conserving surgery reoperation rates and costs, potentially shaping Perimeter’s commercial and market access strategies. The partnership underscores the commitment to innovation in surgical oncology, with implications for improving patient and provider experiences and expanding the technology’s application beyond breast tissue.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI Achieves Record Revenue and Advances AI-Enabled Imaging Technology

Perimeter Medical Imaging AI reported record revenue for the first quarter of 2025, driven by significant commercial traction of its FDA-cleared Perimeter S-Series device. The company achieved several commercial milestones, including increased case volumes and substantial billings. Additionally, Perimeter is advancing its next-generation Perimeter B-Series device, which incorporates AI technology, and has submitted a Premarket Approval application to the FDA. The pivotal trial results for the B-Series, presented at the American Society of Breast Surgeons meeting, showed promising outcomes, potentially transforming surgical practices by improving intraoperative decision-making and reducing re-excisions.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI to Announce Q1 2025 Financial Results

Perimeter Medical Imaging AI announced it will release its first quarter 2025 financial results on May 13, 2025, followed by a webcast and conference call to discuss the outcomes and provide a corporate update. This announcement is significant as it offers stakeholders insights into the company’s financial health and operational progress, potentially impacting its market positioning and future strategic decisions.

Perimeter Medical Imaging AI’s B-Series OCT Achieves Pivotal Trial Success

Perimeter Medical Imaging AI announced successful results from a pivotal trial of its B-Series OCT with ImgAssist AI 2.0, presented at the American Society of Breast Surgeons 2025 meeting. The trial demonstrated a statistically significant reduction in residual cancer during surgery, meeting its primary endpoint and showcasing the device’s potential to improve surgical outcomes by reducing re-excisions and enhancing intraoperative decision-making. The company has submitted a Premarket Approval application to the FDA, marking a significant milestone in its regulatory journey.